001     119617
005     20240228134945.0
024 7 _ |a 10.1016/j.ajpath.2013.12.016
|2 doi
024 7 _ |a pmid:24513261
|2 pmid
024 7 _ |a 0002-9440
|2 ISSN
024 7 _ |a 1525-2191
|2 ISSN
037 _ _ |a DKFZ-2017-00248
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Barthelmeß, Sarah
|b 0
245 _ _ |a Solitary fibrous tumors/hemangiopericytomas with different variants of the NAB2-STAT6 gene fusion are characterized by specific histomorphology and distinct clinicopathological features.
260 _ _ |a New York [u.a.]
|c 2014
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1520584871_26905
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Recurrent somatic fusions of the two genes, NGFI-A-binding protein 2 (NAB2) and STAT6, located at chromosomal region 12q13, have been recently identified to be presumable tumor-initiating events in solitary fibrous tumors (SFT). Herein, we evaluated a cohort of 52 SFTs/hemangiopericytomas (HPCs) by whole-exome sequencing (one case) and multiplex RT-PCR (all 52 cases), and identified 12 different NAB2-STAT6 fusion variants in 48 cases (92%). All 52 cases showed strong and diffuse nuclear positivity for STAT6 by IHC. We categorized the fusion variants according to their potential functional effects within the predicted fusion protein and found strong correlations with relevant clinicopathological features. Tumors with the most common fusion variant, NAB2ex4-STAT6ex2/3, corresponded to classic pleuropulmonary SFTs with diffuse fibrosis and mostly benign behavior and occurred in older patients (median age, 69 years). In contrast, tumors with the second most common fusion variant, NAB2ex6-STAT6ex16/17, were found in much younger patients (median age, 47 years) and represented typical HPCs from deep soft tissue with a more aggressive phenotype and clinical behavior. In summary, these molecular genetic findings support the concept that classic pleuropulmonary SFT and deep-seated HPC are separate entities that share common features but correlate to different clinical outcome.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a NAB2 protein, human
|2 NLM Chemicals
650 _ 7 |a Repressor Proteins
|2 NLM Chemicals
650 _ 7 |a STAT6 Transcription Factor
|2 NLM Chemicals
650 _ 7 |a STAT6 protein, human
|2 NLM Chemicals
700 1 _ |a Geddert, Helene
|b 1
700 1 _ |a Boltze, Carsten
|b 2
700 1 _ |a Moskalev, Evgeny A
|b 3
700 1 _ |a Bieg, Matthias
|0 P:(DE-He78)e247efc0264a7b0e4bae09804002d4e1
|b 4
|u dkfz
700 1 _ |a Sirbu, Horia
|b 5
700 1 _ |a Brors, Benedikt
|0 P:(DE-He78)fc949170377b58098e46141d95c72661
|b 6
|u dkfz
700 1 _ |a Wiemann, Stefan
|0 P:(DE-He78)f6bebe05e7a748d3cbf9f59659567d52
|b 7
|u dkfz
700 1 _ |a Hartmann, Arndt
|b 8
700 1 _ |a Agaimy, Abbas
|b 9
700 1 _ |a Haller, Florian
|b 10
773 _ _ |a 10.1016/j.ajpath.2013.12.016
|g Vol. 184, no. 4, p. 1209 - 1218
|0 PERI:(DE-600)1480207-7
|n 4
|p 1209 - 1218
|t The American journal of pathology
|v 184
|y 2014
|x 0002-9440
909 C O |p VDB
|o oai:inrepo02.dkfz.de:119617
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)e247efc0264a7b0e4bae09804002d4e1
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)fc949170377b58098e46141d95c72661
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)f6bebe05e7a748d3cbf9f59659567d52
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2014
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b AM J PATHOL : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)B080-20160331
|k B080
|l Theoretische Bioinformatik
|x 0
920 1 _ |0 I:(DE-He78)B050-20160331
|k B050
|l Molekulare Genomanalyse
|x 1
920 1 _ |0 I:(DE-He78)W110-20160331
|k W110
|l Microarray Unit
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B080-20160331
980 _ _ |a I:(DE-He78)B050-20160331
980 _ _ |a I:(DE-He78)W110-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21